Neuropeptide and Kinin antagonists

Handbook of Experimental Pharmacology

Volumn 177, Issue , 2007, Pages 181-216

  Hill, R G ^a   Oliver, K R ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Bradykinin; CGRP; Des Arg bradykinin; Kinins; Peptides; Substance P

Indexed keywords

ANALGESIC AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; KININ; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; SUBSTANCE P;

ANIMAL; DRUG ANTAGONISM; GENETICS; HUMAN; PAIN; PHYSIOLOGY; REVIEW; TRANSGENIC ANIMAL;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; KININS; NEUROPEPTIDES; PAIN; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 34447117672     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-33823-9_7     Document Type: Article

References (240)

1. AiyarN, DainesRA, Disa J, et al (2001) Pharmacology of SB-273779, a non-peptide calcitonin gene related peptide 1 receptor antagonist. J Pharmacol Exp Ther 296:768-775
2. Amara SG, Jonas V, Rosenfeld MG, et al (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244
3. Ambalavanar R, MoritaniM, Moutanni A, et al (2006) Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviours which are modulated by a neuropeptide antagonist. Pain 120:53-68
4. AndersonLE, SeyboldVS (2004) Calcitonin gene relatedpeptide regulates gene transcription in primary afferent neurons. J Neurochem 91:1417-1429
5. Ashina M, Bendtsen L, Jensen R, et al (2000) Evidence for increased plasma levels of calcitonin gene related peptide in migraine outside of attacks. Pain 86:133-138
6. Aubel B, Kayser V, Mauborgne A, et al (2004) Antihyperalgesic effects of cizolirtine in diabetic rats: behavioural and biochemical studies. Pain 110:22-32
7. Awawdeh L, Lundy FT, Shaw C, et al (2002) Quantitative analysis of substance P, neurokinin A and calcitonin gene-related peptide in pulp tissue from painful and healthy human teeth. Int Endod J 35:30-36
8. Ballet S, Aubel B, Mauborgne A, et al (2001) The novel analgesic cizolirtine inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology 40:578-589
9. Baptista HA, Avellar MCW, Araujo RC, et al (2002) Transcriptional regulation of the rat bradykinin B2 receptor gene: identification of a silencer element. Mol Pharmacol 62:1344-1355
10. Bellamy JL, Cady RK, Durham PL (2006) Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46:24-33
11. Bennett AD, Chastain KM, Hulseboch CE (2000) Alleviation of mechanical and thermal allodynia by CGRP 8-37 in a rodent model of chronic central pain. Pain 86:163-175
12. BeresfordIJ, BirchPJ, HaganRM, et al (1991) Investigationinto species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96, 345. Br J Pharmacol 104: 292-293
13. Binder W, Scott C, Walker JS (1999) Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR 205171. Eur J Neurosci 11:2065-2072
14. Block GA, Rue D, Panebianco D, et al (1998) The substance P receptor antagonist L-754, 030 (MK-0869) is ineffective in he treatment of postherpetic neuralgia. Neurology 4:A225
15. Bock MG, Longmore J (2000) Bradykinin antagonists: new opportunities. Curr Opin Chem Biol 4:401-406
16. Boix F, Roe C, Rosenborg L, Knardahl S (2005) Kinin peptides in human trapezius muscle during sustained isometric contraction and their relation to pain. J Appl Physiol 98: 534-540
17. Borkowki JA, RansomRW, Seabrook GR, et al (1995) Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smoothmuscle and neurons. J Biol Chem 270:13706-13710
18. Boscan P, Dutschmann M, HerbertH, Paton JFR (2005) Neurokininergicmechanism within the lateral crescent nucleus of the parabrachial complex participates in the heart rate response to nociception. J Neurosci 25:1412-1420
19. Bowen EJ, Schmidt TW, Firm CS, et al (2006) Tumour necrosis factor α stimulation of calcitonin gene related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem 96:65-77
20. Boyce S, Hill RG (2000) Discrepant results from preclinical and clinical studies on the potential of substance P-receptor antagonists compounds as analgesics. In: Devor M, Rowbotham MC, Wiesenfield-Hallin Z (eds) Proceedings of the 9th World Congress on Pain. IASP press, Seattle, pp 313-324
21. Boyce S, Hill RG (2004) Substance P (NK1) receptor antagonists-analgesics or not? In: Holzer P (ed) Tachykinins. (Handbook of experimental pharmacology, vol 164) Springer, Berlin Heidelberg New York, pp 441-457
22. Boyce S, Laird JMA, Tattersall FD, et al (1993) Antinociceptive effects of NK1 receptor antagonists: comparison of behavioural and electrophysiological tests. 7thWorld Congress on Pain. Abstr 641
23. Boyce S, Ali Z, Hill RG (2001) New developments in analgesia. Drug DiscovWorld 4:31-35
24. Brain SD, Grant AD (2004) Vascular actions of calcitonin gene related peptide and adrenomedullin. Physiol Rev 84:903-934
25. Brain SD, Poyner DR, Hill RG (2002) CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? Trends Pharmacol Sci 23:51-53
26. BregolaG, VaraniK, Gessi S, et al (1999) Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy. Neuroscience 92: 1043-1049
27. Burgess GM, Perkins MN, Rang HP, et al (2000) Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 129:77-86
28. Cabrini D.A., Campos MM, Tratsk KS, et al (2001) Molecular and pharmacological evidence formodulation of kinin B1 receptor expression by endogenous glucocorticoid hormones in rats. Br J Pharmacol 132:567-577
29. Calixto JB, Cabrini D.A., Ferreira J, et al (2000) Kinins in pain and inflammation. Pain 87:1-5
30. Calixto JB, Cabrini D.A., Ferreira J, et al (2001) Inflammatory pain: kinins and antagonists. Curr Opin Anaesthesiol 14:519-526
31. Calixto JB, Medeiros R, Fernandes ES, et al (2004) Kinin B1 receptors: key G-proteincoupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143:803-818
32. Cascieri MA, Ber E, Fong TM, et al (1992) Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.Mol Pharmacol 42:458-463
33. Chopra B, Barrick SR, Meyers S, et al (2005) Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 562:859-871
34. Chuang HH, Prescott ED, Kong H, et al (2001) Bradykinin and nerve growth factor release the capsaicin receptor from Ptdlns (4, 5) P2-mediated inhibition. Nature 411:957-962
35. Conley RK, Wheeldon A, Webb JK, et al (2005) Inhibition of acute nociceptive responses in rat spinal cord by a bradykinin B1 receptor antagonist. Eur J Pharmacol 527:44-51
36. Connor HE, Bertin L, Gillies S, et al (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia 18:392
37. Coudore-Civiale M, Courteix C, Boucher M, et al (2000) Evidence for an involvement of tachykinins in allodynia in streptozocin-induced diabetic rats. Eur J Pharmacol 40: 47-53
38. Couture R, Harrisson M, Vianna RM, et al (2001) Kinin receptors in pain and inflammation. Eur J Pharmacol 429:161-176
39. Cridland RA, Henry JL (1986) Comparison of the effects of substance P, neurokinin A, physalaemin and eledoisin in facilitating a nociceptive reflex in the rat. Brain Res 381: 93-99
40. Cruwys SC, Garrett NE, Perkins MN, et al (1994) The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol 113:940-944
41. CumberbatchMJ, Carlson E, Wyatt A, et al (1998) Reversal of behavioural and electrophysiological correlates of experimental peripheral neuropathy by the NK1 receptor antagonist GR205171 in rats. Neuropharmacology 37:1535-1543
42. CumberbatchMJ, Williamson DJ, Mason GS, et al (1999) Dural vasodilation causes a sensitization of rat caudal trigeminal nucleus neurons in vivo that is blocked by a 5-HT 1B/1D agonist. Br J Pharmacol 126:1478-1486
43. Daemen MA, Kurvers HA, Kitslaar PJ, et al (1998) Neurogenic inflammation in an animal model of neuropathic pain. Neurol Res 20:41-45
44. Daines RA, Sham KKC, Taggart JJ, et al (1997) Quinine analogues as non-peptide calcitonin gene related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett 7:2673-2676
45. De Felipe C, Herrero JF, OBrienA, et al (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392:394-397
46. Delafoy L, Gelot A, ArdidD, et al (2006) Interactive involvement of BDNF, NGF and CGRP in colonic hypersensitivity in the rat Gut. Published online 9 Jan 2006. http://gut.bmjjournals.com/cgi/content/abstract/gut.2005.064063v1. Cited 16 May 2006
47. Dickenson A, Besson JM (eds) (1997) The pharmacology of pain. (Handbook of experimental pharmacology, vol 130) Springer, Berlin Heidelberg New York
48. Dionne RA (1999) Clinical analgesic trials of NK1 antagonists. Curr Opin Investig Drugs 1:82-85
49. DionneRA, MaxMB, Gordon SM, et al (1998) The substance P receptor antagonistCP-99, 994 reduces acute postoperative pain. Clin Pharmacol Ther 64:562-568
50. Dlamini Z, Bhoola KD (2005) Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol 58:915-922
51. Duggan AW, Furmidge LJ (1994) Probing the brain and spinal cord with neuropeptides in pathways related to pain and other functions. Front Neuroendocrinol 15:275-300
52. Duggan AW, Morton CR, Zhao ZQ, et al (1987) Noxious heating of the skin releases immunoreactive substance P in the substantia gelatinosa of the cat: a study with antibody microprobes. Brain Res 403:345-349
53. Dziadulewicz EK, Ritchie TJ, Hallett A, et al (2002) Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orallyactive human bradykinin B2 receptor antagonists. J Med Chem 45:2160-2172
54. Ebersberger A, Charbel Issa P, Vanegas H, Schaible HG (2000) Differential effects of calcitonin gene related peptide and calcitonin gene related peptide 8-37 upon responses to NMDA or AMPA in spinal nociceptive neurons with knee joint input in the rat. Neuroscience 99:171-178
55. Edvinsson L (2001) Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 15:745-753
56. Edvinsson L, Goadsby PJ (1995) Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 15:272-276
57. Edvinsson L, Olesen IJ, Kingman TA, et al (1995) Modification of vasoconstrictor responses in cerebral blood vessels by lesioning of the trigeminal nerve: possible involvement of CGRP. Cephalalgia 15:373-383
58. Eisenbarth H, Rukwied R, Petersen M, et al (2004) Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin. Pain 110:197-204
59. Fang LN, Wang ZZ, Wang YL, et al (2004) Expression of calcitonin gene related peptide type 1 receptor mRNA and the activity modifying proteins in the rat nucleus accumbens. Neurosci Lett 362:146-149
60. Fernandes ES, Passos GF, Campos MM, et al (2005) Cytokines and neutrophils as important mediators of platelet-activating factor-induced kinin B1 receptor expression. Br J Pharmacol 146:209-216
61. Fernihough J, Gentry C, Bevan S, Winter J (2005) Regulation of calcitonin gene related peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett 388:75-80
62. Ferreira J, Campos MM, Pesquero JB, et al (2001) Evidence for the participation of kinins in Freunds adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology 41:1006-1012
63. Ferreira J, Campos MM, Arajo R, et al (2002) The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterise the nociceptive responses caused by kinins at the spinal level. Neuropharmacology 43:1188-1197
64. Ferreira J, Beirith A, Mori MAS, et al (2005) Reduced nerve injury-induced neuropathic pain in kinin B1 receptor knock-out mice. J Neurosci 25:2405-2412
65. Ferreira PK, Campos MM, Calixto JB (2000) The role of sensorial neuropeptides in the edematogenic responses mediated by B1 agonist des-Arg9-BK in rats pre-treated with LPS. Regul Pept 89:29-35
66. Field MJ, McCleary S, Boden P, et al (1998) Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat. J Pharmacol Exp Ther 285:1226-1232
67. FieldMJ, GonzalezMI, Tallarida RJ, et al (2002) Gabapentin and the neurokinin (1) receptor antagonist CI-1021 act synergistically in two ratmodels of neuropathic pain. J Pharmacol Exp Ther 303:730-735
68. Fischer MJM, Koulchitsky S, Messlinger K (2005) The nonpeptide calcitonin gene related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 25:5877-5883
69. Fox A, Kaur S, LiB, et al (2005) Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br J Pharmacol 144:889-899
70. Gabra BH, Sirois P (2005) Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor. Eur J Pharmacol 514:61-67
71. Gabra BH, Benrezzak O, Pheng LH, et al (2005) Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worcester rats: efficacy of a selective bradykinin B1 receptor antagonist. J Neuropathol Exp Neurol 64:782-789
72. Gallai V, Sarchielli P, Floridi A, et al (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384-390
73. Ganju P, Davis A, Patel S, et al (2001) p38 stress-activated protein kinase inhibitor reverses bradykinin B1 receptor-mediated component of inflammatory hyperalgesia. Eur J Pharmacol 421:191-199
74. Garret C, Carruette A, Fardin V, et al (1992) RP 67580, a potent and selective substance P non-peptide antagonist. C R Acad Sci III 314:199-204
75. Garry EM, Jones E, Fleetwood-Walker SM (2004) Nociception in vertebrates: key receptors participating in spinalmechanisms of chronic pain in animals. Brain Res Rev 46:216-224
76. Gebre-Medhin S, Mulder H, Zhang Y, et al (1998) Reduced nociceptive behaviour in islet amyloid polypeptide (amylin) knockout mice. Mol Brain Res 63:180-183
77. Goadsby PJ (1993) Inhibition of calcitonin gene related peptide by h-CGRP (8-37) antagonises the cerebral dilator response fromnasociliary nerve stimulation in the cat.Neurosci Lett 151:13-16
78. GoldsteinDJ, WangO (1999) Lanepitant, anNK1 antagonist, in painful diabetic neuropathy. Clin Pharmacol Therap 65 (Abstr)
79. Goldstein DJ, Wang O, Saper JR, et al. 1997. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia, 17:785-790
80. Goldstein DJ, Wang O, Todd TE (1998) Lanepitant in osteoarthritis pain. Clin Pharmacol Ther 63:168
81. Goldstein DJ, Offen WW, Klein EG (1999) Lanepitant, an NK1 antagonist, in migraine prophylaxis. Clin Pharmacol Ther 65:Abstr Gonzalez MI, Field MJ, Hughes J, Singh L (2000) Evaluation of selective NK (1) receptor antagonist CI-1021 in animalmodels of inflammatory and neuropathic pain. J Pharmacol Exp Ther 294:444-450
82. Goto T, Tanaka T (2002) Tachykinins and tachykinin receptors in bone. Microsc Res Tech 58:91-97
83. Gougat J, Ferrari B, Sarran L, et al (2004) SSR240612 [ (2R) -2-[ ( (3R) -3- (1, 3-benzodioxol-5- yl) -3-[ (6-methoxy-2-naphthyl) sulfonyl] aminopropanoyl) amino]-3- (4-[2R, 6S) -2, 6-di methylpiperidinyl]methylphenyl) -N-isopropyl -N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309:661-669
84. Guzman F, Braun C, Lim RKS, et al (1964) Narcotic and non-narcotic analgesics which block visceral pain evoked by intra-arterial injection of bradykinin and other algesic agents. Arch Int Pharmacodyn Ther 149:571-588
85. Han JS, LiW, NeugebauerV (2005) Critical role of calcitonin gene related peptide 1 receptors in the amygdala in synaptic plasticity and pain behaviour. J Neurosci 25:10717-10728
86. Hanesch U, Pfrommer U, Grubb BD, Schaible HG (1993) Acute and chronic phases of unilateral inflammation in rats ankle are associatedwith an increase in the proportion of calcitonin gene relatedpeptide-immunoreactivedorsal root ganglioncells.Eur JNeurosci 5:154-161
87. Hargreaves R (2002) Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 63 Suppl:18-24
88. HayDL, ConnerAC, Howitt SG, et al (2004) The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors. J Mol Neurosci 22:105-113
89. Hay DL, Poyner DR, Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 109:173-197
90. Henry JL (1976) Effects of substance P on functionally identified units in cat spinal cord. Brain Res 114:439-451
91. Henry MA, Nouser-Goebl NA, Westrum LE (1993) Light and electron microscopic localization of calcitonin gene related peptide immunoreactivity in lamina II of the feline trigeminal pars caudalis/medullary dorsal horn. Synapse 13:99-107
92. Hershey JC, Corcoran HA, Baskin EP, et al (2005) Investigation of the species selectivity of a non-peptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 127:71-77
93. Hess JF, Ransom RW, Zeng Z, et al (2004) Generation and characterization of a human bradykinin receptor B1 transgenic rat as a pharmacodynamic model. J Pharmacol Exp Ther 10:488-497
94. Hill RG (2001) Molecular basis for the perception of pain. Neuroscientist 7:282-292
95. Hill RG, Rupniak NMJ (1999) Tachykinin receptors and the potential of tachykinin antagonists as clinically effective analgesics and anti-inflammatory agents. In: Brain SB, Moore PK (eds) Pain and neurogenic inflammation. Birkhauser, Basel, pp 313-333
96. Hingten CM, Roy SL, Clapp DW (2006) Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene. Neuroscience 137:637-645
97. Hokfelt T, ArvidssonU, Ceccatelli S, et al (1992) Calcitonin-gene related peptide in the brain, spinal cord and some peripheral systems. Ann NY Acad Sci 657:119-134
98. Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M (2000) Neuropeptides-an overview. Neuropharmacology 39:1337-1356
99. Hokfelt T, Kuteeva E, StanicD, LjungdahlA (2004) The histochemistry of tachykinin systems in the brain. In: Holzer P (ed) Tachykinins (Handbook of experimental pharmacology, vol 164) . Springer, Berlin, Heidelberg, New York, pp 64-120
100. Honore P, Mantyh P (2000) Bone cancer pain: from mechanism to model to therapy. Pain Med 1:303-309
101. Hunt SP, Mantyh PW (2001) The molecular dynamics of pain control. Nat Rev Neurosci 2:83-91
102. Hutchins B, Spears R, Hinton RJ, Harper RP (2000) Calcitonin gene related peptide and substance P immunoreactivity in rat trigeminal ganglia and brainstem following adjuvantinduced inflammation of the temporomandibular joint. Arch Oral Biol 45:335-345
103. Ichikawa H, Sugimoto T (2002) The co-expression of ASIC3 with calcitonin gene related peptide and parvalbumin in the rat trigeminal ganglion. Brain Res 943:287-291
104. Iyengar S, Hipskind PA, Gehlert DR, et al (1997) LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther 280:774-785
105. Jang JH, Nam TS, Paik KS, Leem JW (2004) Involvement of peripherally released substance P and calcitonin gene related peptide inmediating mechanical hyperalgesia in a traumatic neuropathy model of the rat. Neurosci Lett 360:129-132
106. Jones C, Phillips E, Davis C, et al (1999) Molecular characterisation of cloned bradykinin B1 receptors from rat and human. Eur J Pharmacol 374:423-433
107. JuliusD, BasbaumA (2005) A neuropeptide courier for ?-opioid receptors? Cell 122:496-498
108. Julius D, Basbaum AI (2001) Molecular mechanisms of nociception. Nature 413:203-210
109. Juranek I, Lembeck F (1997) Afferent C-fibres release substance P and glutamate. Can J Physiol Pharmacol 75:661-664
110. Just S, Leipold-Buttner C, Heppelmann B (2001) Histological demonstration of voltage dependent calcium channels on calcitonin gene related peptide immunoreactive nerve fibres in the mouse knee joint. Neurosci Lett 312:133-136
111. Kang DS, Ryberg K, Morgelin M, Leeb-Lundberg LM (2004) Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with enhanced. signaling capacity. J Biol Chem 279:22102-22107
112. Kang DS, Gustafsson C, Mgelin M, et al (2005) B1 bradykinin receptor homo-oligomers in receptor cell surface expression and signaling: effects of receptor fragments. Mol Pharmacol 67:309-318
113. Kayser V, Farre A, Hamon M, Bourgoin S (2003) Effects of the novel analgesic cizolirtine in a rat model of neuropathic pain. Pain 104:169-177
114. Kerezoudis NP, Olgart L, Edwall L (1994) CGRP (8-37) reduces the duration but not the maximal increase of antidromic vasodilation in dental pulp and lip of the rat. Acta Physiol Scand 151:73-81
115. King T, Gardell LR, Wang R, et al (2005) Role of NK-1 transmission in opioid-induced hyperalgesia. Pain 116:276-288
116. Kinloch RA, Cox PJ (2005) New targets for neuropathic pain therapeutics. Expert Opin Ther Targets 9:685-698
117. Kuraishi Y, Nanayama T, Ohno H, et al (1988) Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene related peptide. Neurosci Lett 92:325-329
118. Laird JM, Hargreaves RJ, Hill RG (1993) Effect of RP 67580, a non-peptide neurokinin1 receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the rat. Br J Pharmacol 109:713-718
119. Laird JM, Olivar T, Roza C, et al (2000) Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience 98:345-352
120. Laird JM, Roza C, De Felipe C, et al (2001) Role of central and peripheral tachykinin NK1 receptors in capsaicin-induced pain and hyperalgesia in mice. Pain 90:97-103
121. Lassen LH, Haderslev PA, Jacobsen VB, et al (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54-61
122. Leah JD, Cameron AA, Snow PJ (1985) Neuropeptides in physiologically identified mammalian sensory neurons. Neurosci Lett 23:257-263
123. Leeb-Lundberg LM, Kang DS, Lamb ME, et al (2001) The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. J Biol Chem 276:8785-8792
124. Levy D, Zochodne DW (2000) Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain 86:265-271
125. Levy D, Burstein R, Strassman AM (2005) Calcitonin gene related peptide does not excite or sensitisemeningeal nociceptors: implications for the pathophysiology ofmigraine. Ann Neurol 58:698-705
126. LevyMJ, Classey JD, Manreesri S, et al (2004) The association between calcitonin gene related peptide (CGRP) , substance P and headache in pituitary tumours. Pituitary 7:67-71
127. Li JL, Ding YQ, Xiong KH, Li JS, et al (1998) Substance P receptor (NK1) -immunoreactive neurons projecting to the periaqueductal gray: distribution in the spinal trigeminal nucleus and the spinal cord of the rat. Neurosci Res 30:219-225
128. Limmroth V, Katsarava Z, Liedert B, et al (2001) An in vivo model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain 92:101-106
129. Littman B, Newton FA, Russell IJ (1999) Substance P antagonism in fibromyalgia: a trial with CJ-11, 974. 9thWorld Congress of Pain, abstr 218, p 67
130. Liu HX, Hokfelt T (2002) The participation of galanin in pain processing at the spinal level. Trends Pharmacol Sci 23:468-474
131. Lofgren O, Yu LC, Theodorsson E, et al (1997) Intrathecal CGRP (8-37) results in a bilateral increase in the hindpaw withdrawal latency in rats with a unilateral thermal injury. Neuropeptides 31:601-607
132. Lopes P, Couture R (1997) Localization of bradykinin-like immunoreactivity in the rat spinal cord: effects of capsaicin, melittin, dorsal rhizotomy and peripheral axotomy. Neuroscience 78:481-497
133. Lu JT, Son YJ, Lee J, et al (1999) Mice lacking α-calcitonin gene related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci 14:99-120
134. Ma QP, Hill R, Sirinathsinghji D (2001) Colocalization of CGRP with 5-HT 1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur J Neurosci 13:2099-2104
135. MaW, Ramer MS, Bisby MA (1999) Increased calcitonin related peptide immunoreactivity in gracile nucleus after partial sciatic nerve injury: age dependent and originating from spared sensory neurons. Exp Neurol 159:459-473
136. Ma W, Chabot JG, Powell KJ, et al (2003) Localization and modulation of calcitonin gene related peptide receptor component protein immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 120:677-694
137. Mansikka H, Shiotani M, Winchurch R, et al (1999) Neurokinin-1 receptors are involved in behavioral responses to high-intensity heat stimuli and capsaicin-induced hyperalgesia in mice. Anesthesiology 90:1643-1649
138. Mansikka H, Sheth RN, DeVries C, Lee H, Winchurch R, Raja SN (2000) Nerve injuryinducedmechanical but not thermal hyperalgesia is attenuated in neurokinin-1 receptor knockout mice. Exp Neurol 162:343-349
139. Mantyh PW, Hunt SP (1985) The autoradiographic localization of substance P receptors in the rat and bovine spinal cord and the rat and cat spinal trigeminal nucleus pars caudalis and the effects of neonatal capsaicin. Brain Res 332:315-324
140. Mantyh PW, DeMaster E, Malhotra A, et al (1995) Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268:1629-1632
141. Mantyh PW, Rogers SD, Honore P, et al (1997) Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 278:275-279
142. Marceau F, Regoli D (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3:845-852
143. Marceau F, Hess JF, BachvarovDR (1998) The B1 receptor for kinins. Pharmacol Rev 50:358-382
144. Martinez-Caro L, Laird JM (2000) Allodynia and hyperalgesia evoked by sciatic mononeuropathy in NKI receptor knockout mice. Neuroreport 11:1213-1217
145. Mason GS, Cumberbatch MJ, Hill RG, et al (2002) The bradykinin B1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbits. Can J Physiol Pharmacol 80:264-268
146. Matthew IR, Ogden GR, Frame JW, Wight AJ (2000) Dose response and safety of cizolirtine citrate (E-4018) in patients with pain following extraction of third molars. CurrMed Res Opin 16:107-114
147. MaxMB, Schafer SC, CulnaneM, et al (1988) Association of pain reliefwith drug side-effects in postherpetic neuralgia: a single-dose study clonidine, codeine, ibuprofen and placebo. Clin Pharmacol Ther 43:363-371
148. Mazzuferi M, Binaschi A, Rodi D, et al (2005) Induction of B1 bradykinin receptors in the kindled hippocampus increases extracellular glutamate levels: a microdialysis study. Neuroscience 135:979-986
149. McLean PG, Perretti M, Ahluwalia A (2000) Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 48:194-210
150. McLean S, Ganong AH, Seeger TF, et al (1991) Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 251:437-439
151. Mogil JS, Miermeister F, Seifert F, et al (2005) Variable sensitivity to noxious heat ismediated by differential expression of the CGRP gene. Proc Natl Acad Sci U S A 102:12938-12943
152. Molander C, Ygge J, Dalsgaard CJ (1987) Substance P-, somatostatin- and calcitonin generelated peptide-like immunoreactivity and fluoride resistant acid phosphatase-activity in relation to retrogradely labeled cutaneous, muscular and visceral primary sensory neurons in the rat. Neurosci Lett 74:37-42
153. Moreno MJ, Abounader R, Hebert E, et al (2002) Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 42:568-576
154. Morissette G, Fortin JP, Otis S, et al (2004) A novel nonpeptide antagonist of the kinin B1 receptor: effects on the rabbit receptor. J Pharmacol Exp Ther 311:1121-1130
155. MorrisR, CheunsuangO, Stewart A, MaxwellD (2004) Spinal dorsal horn neurone targets for nociceptive primary afferents: do single neurone morphological characteristics suggest how nociceptive information is processed at the spinal level. Brain Res Brain Res Rev 46:173-190
156. Muff R, Born W, Lutz TA, Fischer JA (2004) Biological importance of the peptides of the calcitonin family as revealed by disruption and transfer of corresponding genes. Peptides 25:2027-2038
157. Nagy JI, Hunt SP, Iversen LL, et al (1981) Biochemical and anatomical observations on the degeneration of peptide-containing primary afferent neurons after neonatal capsaicin. Neuroscience 6:1923-1934
158. Natsugari H, Ikeura Y, Kiyota Y, et al (1995) Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3, 4-b]pyridine. J Med Chem 38:3106-3120
159. Navari RM, Reinhardt RR, Gralla RJ, et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. N Engl J Med 340:190-195
160. Nawa H, Kotani H, Nakanishi S (1984) Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature 312:729-734
161. Neckers LM, Schwartz JP, Wyatt RJ, et al (1979) Substance P afferents from the habenula innervate the dorsal raphe nucleus. Exp Brain Res 37:619-623
162. Neugebauer V, Rumenapp P, Schaible HG (1996) Calcitonin gene related peptide is involved in the spinal processing of mechanosensory input from the rats knee joint and in the generation and maintenance of hyperexcitability of dorsal horn neurons during development of acute inflammation. Neuroscience 71:1095-1109
163. Nohr D, Schafer MKH, Persson S, et al (1999) Calcitonin gene related peptide gene expression in collagen-induced arthritis is differentially regulated in primary afferents and motoneurons: influence of glucocorticoids. Neuroscience 93:759-773
164. Norman B, Panebianco D, Block GA (1998) A controlled, in clinic study to explore the preliminary safety and efficacy of intravenous L-758, 298 (a prodrug of the NK1 receptor antagonist L-754, 030) in the acute treatment of migraine [abstract]. Cephalalgia 18:407
165. Oh-hashi Y, Shindo T, Kurihara Y, et al (2001) Elevated sympathetic nervous activity inmice deficient in α-CGRP. Circ Res 89:983-990
166. Okano S, Ikeura Y, Inatomi N (2002) Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 300:925-931
167. Okayama Y, Ono Y, Nakazawa T, et al (1998) Human skin mast cells produce TNF-alpha by substance P. Int Arch Allergy Immunol 117 Suppl 1:48
168. Olesen J, Diener HC, Husstedt IW, et al (2004) Calcitonin gene related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N Engl J Med 350: 1104-1110
169. Oliver KR, SirinathsinghjiDJ, Hill RG (2000) Frombasic research on neuropeptide receptors to clinical benefit. Drug News Perspect 13:530-542
170. Oliver KR, Kane SA, Salvatore CA, et al (2001) Cloning, characterization and central nervous system distribution of rat receptor activity modifying proteins. Eur J Neurosci 14: 618-628
171. Oliver KR, Wainright A, Edvinsson L, Pickard JD, Hill RG (2002) Immunochemical localization of calcitonin-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22:620-629
172. Opree A, Kress M (2000) Involvement of the proinflammatory cytokines tumor necrosis factor α, IL-1β and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 20: 6289-6293
173. Patel S, Gentry CT, Campbell EA (1996) A model for in vivo evaluation of tachykinin NK1 receptor antagonists using carrageenan-induced hyperalgesia in the guinea pig paw. Br J Pharmacol 117:248P
174. Patte-Mensah C, Kibaly C, Mensah-Nyagan AG (2005) Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception. Proc Natl Acad Sci U S A 102:9044-9049
175. Patwardhan AM, Berg KA, Akopain AN, et al (2005) Bradykinin-induced functional competence and trafficking of the ?-opioid receptor in trigeminal nociceptors. J Neurosci 25:8825-8832
176. Pavlik I, Suchy J, Pac D, et al (2004) Comparison of cizolirtine citrate andmetamizol sodium in the treatment of adult acute renal colic: a randomized double blind clinical pilot study. Clin Ther 26:1061-1072
177. Pesquero JB, Araujo RC, Heppenstall PA, et al (2000) Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97:8140-8145
178. Petersen KA, Lassen LH, Birk S, et al (2005) BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77:202-213
179. Phebus LA, JohnsonKW, StengelPW, et al (1997) The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci 60:1553-1561
180. Piper RD, Edvinsson L, Ekman R, Lambert GA (1993) Cortical spreading depression does not result in the release of calcitonin gene related peptide into the external jugular vein of the cat: relevance to human migraine. Cephalalgia 13:180-183
181. PoynerDR, Sexton PM, Marshall I, et al (2002) InternationalUnion of Pharmacology.XXXII. Themammalian calcitonin gene related peptide, adrenomedullin, amylin and calcitonin receptors. Pharmacol Rev 54:233-246
182. Radhakrishnan V, Henry JL (1991) Novel substance P antagonist, CP-96, 345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P. Neurosci Lett 132:39-43
183. Radhakrishnan V, Iyengar S, Henry JL (1998) The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli. Neuroscience 83:1251-1260
184. Raidoo DM, Bhoola KD (1997) Kinin receptors on human neurons. J Neuroimmunol 77: 39-44
185. Ransom RW, Harrell CM, Reiss D, et al (2004) Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist. Eur J Pharmacol 499:77-84
186. RashidMH, InoueM, Matsumoto M, et al (2004) Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J Pharmacol Exp Ther 308:1158-1164
187. Reinhardt RR, Laub JB, Fricke JR, et al (1998) Comparison of the neurokinin-1 antagonist, L-754, 030, to placebo, acetaminophen and ibuprofen in the dental pain model. Clin Pharmacol Ther 63:168
188. Ren K, Novikova SI, He F, et al (2005) Neonatal local noxious insult affects gene expression in the spinal dorsal horn of adult rats. Mol Pain 1:27
189. Richie TJ, Dziadulewicz EK, Culshaw AJ, et al (2004) Potent and orally bioavailable nonpeptide antagonists at the human bradykinin B1 receptor based on a 2-alkylamino-5- sulfamoylbenzamide core. J Med Chem 47:4642-4644
190. Riediger T, Schmid HA, Young AA, Simon E (1999) Pharmacological characterization of amylin-related peptides activating subfornical organ neurons. Brain Res 837:161-168
191. RosenfeldMG, EmesonRB, Yeakley JM, et al (1992) Calcitonin gene relatedpeptide: a peptide generated as a consequence of tissue-specific developmentally regulated alternative RNA processing events. Ann N Y Acad Sci 657:1-17
192. Rudolf K, Eberlein W, Engel W, et al (2005) Development of human calcitonin gene related peptide (CGRP) receptor antagonists .1. potent and selective small molecule CGRP antagonists. 1-[N2[3, 5 dibromo-N-[[4- (3, 4-dihydro-2) 1H) -oxoquinazolin-3yl) -1- piperidinyl]carbonyl]-D-tyrosyl]-L- lysyl]-4- (4-pyridinyl) piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 48:5921-5931
193. Rupniak NM, Boyce S, Williams AR, et al (1993) Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580. Br J Pharmacol 110:1607-1613
194. Rupniak NM, Carlson E, Boyce S, et al (1996) Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733, 060 in gerbils. Pain 67:189-195
195. Rupniak NM, Tattersall FD, Williams AR, et al (1997a) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol 326:201-209
196. Rupniak NMJ, Boyce S, Webb JK, et al (1997b) Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8] bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 7:89-97
197. Rupniak NMJ, Longmore J, Hill RG (2000) Role of bradykinin B1 and B2 receptors in nociception and inflammation. In: Wood JN (ed) Molecular basis of pain induction. Wiley-Liss, Toronto, pp 149-173
198. Russell IJ, Orr MD, Littman B, et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37:1593-1601
199. Sabino MA, Honore P, Rogers SD, et al (2002) Tooth extraction-induced internalization of the substance P receptor in trigeminal nucleus and spinal cord neurons: imaging the neurochemistry of dental pain. Pain 95:175-186
200. Sakai K, Matsuno H, Tsuji H, et al (1998) Substance P receptor (NK1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis. Scand JRheumatol 27:135-141
201. Salt TE, Hill RG (1983) Neurotransmitter candidates of somatosensory primary afferent fibres. Neuroscience 4:1083-1103
202. Samsam M, Covenas R, Ahangari R, et al (2000) Simultaneous depletion on neurokinin A, substance P and calcitonin gene related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain 84:389-395
203. Schubert TEO, Weidler C, Lerch K, et al (2005) Achilles tendinosis is associated with sprouting of substance P positive nerve fibres. Ann Rheum Dis 64:1083-1086
204. Schutz B, Mauer D, Salmon AM, et al (2004) Analysis of the cellular expression pattern of β-CGRP in α-CGRP deficient mice. J Comp Neurol 476:32-43
205. Schwei MJ, Honore P, Rodgers SD, et al (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19:10886-10897
206. Seabrook GR, Bowery BJ, Heavens R, et al (1997) Expression of B1 and B2 bradykinin receptormRNAand their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurons from wild-type and B2 receptor knockout mice. Neuropharmacology 36:1009-1017
207. Seguin L, Millan MJ (1994) The glycine B receptor partial agonist (+) -HA966, enhances induction of antinociception by RP 67580 and CP-99, 994. Eur J Pharmacol 253:R1-3
208. Sergeyev V, Hokfelt T, Hurd Y (1999) Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 10:3967-3970
209. Seybold VS, McCarson KE, Mermelstein PG, et al (2003) Calcitonin gene related peptide regulates expression of neurokinin 1 receptors by rat spinal neurons. J Neurosci 23: 1816-1824
210. Shembalkar P, Taubel J, AbadiasM, et al (2001) Cizolirtine citrate (E-4018) in the treatment of chronic neuropathic pain. Curr Med Res Opin 17:262-266
211. Shepheard SL, Williamson DJ, Hill RG, et al (1993) The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol 108:11-12
212. Shepheard SL, Williamson DJ, Williams J, et al (1995) Comparison of the effects of sumatriptan and the NK1 antagonist CP-99, 994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34:255-261
213. Sibilia V, Pagani F, Lattuada N, et al (2000) Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity. Brain Res 854:79-84
214. Simpson PB, Woollacott AJ, Hill RG, et al (2000) Functional characterization of bradykinin analogues on recombinant human bradykinin B1 and B2 receptors. Eur J Pharmacol 392:1-9
215. Smith D, Hill RG, Edvinsson L, Longmore J (2002) An immunohistochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 22:424-431
216. Su DS, Markowitz MK, DiPardo RM, et al (2003) Discovery of a potent, non-peptide bradykinin B1 receptor antagonist. J Am Chem Soc 125:7516-7517
217. Sun RQ, Tu YJ, Lawand NB, et al (2004) Calcitonin gene related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization. J Neurophysiol 92:2859-2866
218. Tachibana T, Noguchi K, Ruda MA (2002) Analysis of gene expression following spinal cord injury in rat using complementary DNA microarray. Neurosci Lett 327:133-137
219. Tajti J, Uddman R, Edvinsson L (2001) Neuropeptide localization in the migraine generator region of the human brainstem. Cephalalgia 21:96-101
220. Tan KK, Brown MJ, Hargreaves RJ, et al (1995) Calcitonin gene related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene related peptide monoclonal antibody and its Fab fragment. Clin Sci 89:565-573
221. Tan KKC, Brown MJ, Longmore J, et al (1994) Demonstration of the neurotransmitter role of calcitonin gene related peptide (CGRP) by immuno-blockade with anti-CGRP monoclonal antibodies. Br J Pharmacol 111:703-710
222. Tanaka S, Barron KW, Chandler MJ, et al (2001) Low intensity spinal cord stimulation may induce cutaneous vasodilation via CGRP release. Brain Res 896:183-187
223. Troger J, Humpel C, Kremser B, et al (1999) The effects of streptozotocin-induced diabetes mellitus on substance P and calcitonin gene related peptide expression in the rat trigeminal ganglion. Brain Res 842:84-91
224. Urban L, Gentry C, Patel S, et al (1999) SelectiveNK1 receptor antagonists block neuropathic and inflammatory pain in the guinea pig. 9thWorld Congress on Pain (abstr 125) , p 40
225. Urban LA, Fox AJ (2000) NK1 receptor antagonists-are they really without effect in the pain clinic? Trends Pharmacol Sci 21:462-464
226. Van Rossum D, Hanisch UK, Quirion R (1997) Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21:649-678
227. Vellani V, Zachrisson O, McNaughton PA (2004) Functional bradykinin B1 receptors are expressed in nociceptive neurones and are upregulated by the neurotrophin GDNF. J Physiol 560:391-401
228. Wacnik PW, Baker CM, Herron MJ, et al (2005) Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 115:95-106
229. Wang H, Kohno T, Amaya F, et al (2005) Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci 25:7986-7992
230. White FA, Bhangoo SK, Miller RJ (2005) Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov 4:834-844
231. Williamson DJ, Hargreaves RJ (2001) Neurogenic inflammation in the context of migraine. Microsc Res Tech 53:167-178
232. WilliamsonDJ, Shepheard SL, Hill RG, et al (1997) The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 328:61-64
233. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997a) Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene related peptide on dural vessel diameter in the anesthetized rat. Cephalalgia 17:518-524
234. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997b) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17:525-531
235. Wood MR, Kim JJ, HanW, et al (2003) Benzodiazepines as potent and selective bradykinin B1 antagonists. J Med Chem 46:1803-1806
236. Xu P, Van Slambrouck C, Berti-Mattera L, Hall AK (2005) Activin induces tactile allodynia and increases calcitonin gene related peptide after peripheral inflammation. J Neurosci 25:9227-9235
237. Yamamoto T, Yaksh TL (1991) Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96, 345: antinociception in the absence of motor dysfunction. Life Sci 49: 1955-1963
238. Yasuda T, Iwamoto T, Ohara M, et al (1999) The novel analgesic compound OT-7100 (5- n-butyl-7- (3, 4, 5-trimethoxybenzoylamino) pyrazolo[1, 5-a]pyrimidine) attenuates mechanical nociceptive responses in animal models of acute and peripheral neuropathic hyperalgesia. Jpn J Pharmacol 79:65-73
239. Ye Z, Wimalaswansa SJ, Westlund KN (1999) Receptor for calcitonin gene related peptide: localization in the dorsal and ventral spinal cord. Neuroscience 92:1389-1397
240. Yu LC, Weng XH, Wang JW, Lundeberg T (2003) Involvement of calcitonin gene related peptide and its receptor in anti-nociception in the periaqueductal grey of rats. Neurosci Lett 349:1-4